Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Regulatory Round-Up: Research Partners And Parallel Traders

Executive Summary

EU’s Innovative Medicines Initiative Builds On Closer U.S. Ties

You may also be interested in...

Drug Firms Join In Stem Cell R&D Under EU Innovative Medicines Initiative

The latest public-private partnerships to be announced under the EU’s Innovative Medicines Initiative includes the StemBANCC project involving 10 pharmaceutical companies and 23 academic institutions working together to develop patient-derived induced stem cell lines for drug development.

Servier Research Deals Suggest Business-As-Usual For Scandal-Ridden Firm

Still reeling from the Mediator scandal, Servier's two latest cancer research deals suggest the French company is trying to move forward.

Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders

Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts